Standout Papers

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcome... 2019 2026 2021 2023 532
  1. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial (2019)
    Anders Widmark, Adalsteinn Gunnlaugsson et al. The Lancet

Immediate Impact

5 from Science/Nature 50 standout
Sub-graph 1 of 24

Citing Papers

Repeated blood–brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial
2024 Standout
Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses
2023 Standout
2 intermediate papers

Works of Jon Kindblom being referenced

Targeting Stromal Androgen Receptor Suppresses Prolactin-Driven Benign Prostatic Hyperplasia (BPH)
2013
3D modeling of effects of increased oxygenation and activity concentration in tumors treated with radionuclides and antiangiogenic drugs
2011

Author Peers

Author Last Decade Papers Cites
Jon Kindblom 849 284 478 315 37 1.5k
Charles Ludgate 924 217 192 236 41 1.7k
Allison Steigler 1496 207 394 293 49 1.8k
P Rocmans 1185 273 171 351 74 2.0k
David S. Lamb 1388 157 348 290 36 1.6k
B. Yap 857 406 535 240 35 2.0k
J.‐E. Damber 1060 140 144 299 47 1.7k
U. Tunn 864 71 246 378 59 1.4k
Sudershan K. Bhatia 236 273 289 94 41 1.5k
Keen‐Hun Tai 1388 186 446 261 23 1.6k
Kenneth J. Dornfeld 404 280 120 165 36 1.8k

All Works

Loading papers...

Rankless by CCL
2026